Xvivo Perfusion AB (publ) (STO:XVIVO)
Sweden · Delayed Price · Currency is SEK 295.20
-13.80 (-4.47%)
Aug 14, 2026, 5:29 PM CET
Xvivo Perfusion AB Financials Overview
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 895.23 | 812.17 | 822.42 | 597.54 | 415.29 | 258.39 |
Revenue Growth | 8.79% | -1.25% | 37.63% | 43.89% | 60.72% | 43.66% |
Gross Profit Gross Profit Growth | 647 | 599.49 | 616.42 | 445.11 | 296.96 | 188.28 |
Operating Income Operating Income Growth | 117.7 | 94.42 | 90.84 | 5.4 | 4.45 | -18.74 |
Net Income Net Income Growth | 88.57 | 25.16 | 172.18 | 91.82 | 18.43 | 8.15 |
Earnings Per Share EPS Growth | 2.81 | 0.80 | 5.44 | 3.07 | 0.62 | 0.28 |
EPS Growth | -19.96% | -85.31% | 77.35% | 394.72% | 121.43% | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Abdominal Abdominal Growth | 247.59 | 225.32 | 179.42 | 134.04 | 70.86 | 53.71 |
Services Services Growth | 67.09 | 77.53 | 87.76 | 79.14 | 48.08 | 6.05 |
Thoracic Thoracic Growth | 580.55 | 509.32 | 555.24 | 384.36 | 296.35 | 198.63 |
Total Total Growth | 895.23 | 812.17 | 822.42 | 597.54 | 415.29 | 258.39 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 304.97 | 292.09 | 415.52 | 546.09 | 246.55 | 398.7 |
Total Debt Total Debt Growth | 121.62 | 124.72 | 34.04 | 31.44 | 10.01 | 5.72 |
Net Cash (Debt) Net Cash Growth | 183.35 | 167.37 | 381.48 | 514.65 | 236.54 | 392.98 |
Net Cash Growth | -13.59% | -56.13% | -25.88% | 117.58% | -39.81% | 13.24% |
Net Cash Per Share Net Cash Per Share Growth | 5.81 | 5.30 | 12.05 | 17.19 | 8.01 | 13.58 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 236.35 | 101.07 | 111.29 | 46.29 | 27.86 | -12.06 |
Capital Expenditures CapEx Growth | -63.62 | -93.72 | -70.73 | -43.02 | -18.19 | -10.19 |
Free Cash Flow Free Cash Flow Growth | 172.73 | 7.35 | 40.56 | 3.27 | 9.67 | -22.25 |
Free Cash Flow Growth | - | -81.89% | 1139.58% | -66.17% | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 72.27% | 73.81% | 74.95% | 74.49% | 71.50% | 72.87% |
Operating Margin | 13.15% | 11.63% | 11.04% | 0.90% | 1.07% | -7.25% |
Pretax Margin | 14.69% | 4.75% | 24.31% | 15.82% | 5.37% | 2.58% |
Profit Margin | 9.89% | 3.10% | 20.94% | 15.37% | 4.44% | 3.16% |
FCF Margin | 19.30% | 0.90% | 4.93% | 0.55% | 2.33% | -8.61% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 104.99 | 233.59 | 89.46 | 113.04 | 296.26 | 1007.78 |
Forward PE | 60.80 | 51.19 | 92.61 | 199.34 | 111.93 | 211.39 |
P/FCF Ratio | 53.83 | 800.25 | 379.77 | 3172.09 | 564.50 | - |
PS Ratio | 10.39 | 7.24 | 18.73 | 17.37 | 13.15 | 31.80 |